You are here


Medtech startup set to revolutionise cancer diagnostics

"Short of a cure (for cancer), screening or testing is the next best thing," says Mr Reynolds.


A SINGAPORE-based medtech startup that is looking to bring low-cost, simple-to-use cancer diagnostics tests to the masses, is set to revolutionise the global cancer diagnostics market that is projected to hit some US$168.6 billion in 2020.

VolitionRx has developed a blood...

Market voices on: